In Reply Like many other analyses of the costs of diabetes in the United States,1 our study relied on MEPS, which collects data from pharmacies on the costs of medications. The survey does not account for rebates, which involve payments by pharmaceutical companies to payers and intermediaries including pharmacy benefit managers,2 because these rebates are generally not publicly disclosed.
Hua X, Herman WH, Clarke P. Cost of Antihyperglycemic Medications in the United States—Reply. JAMA. 2016;316(6):665–666. doi:10.1001/jama.2016.8596
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.